Is It the Right Time To Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? an Analysis From the Available Evidence

dc.contributor.author Bhattacharya, Sudip
dc.contributor.author Gokdemir, Ozden
dc.contributor.author Bashar, Md Abu
dc.contributor.author Thiyagarajan, Arulmani
dc.contributor.author Singh, Amarjeet
dc.date.accessioned 2023-06-16T14:46:39Z
dc.date.available 2023-06-16T14:46:39Z
dc.date.issued 2021
dc.description.abstract Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. In this regard, India has a prevalence ranging between 2% and 7% with exposure rates of 10%-60%. Hepatitis B is a vaccine-preventable disease. In India, the World Health Organization protocol for hepatitis B vaccination has been followed, and it is given free of cost in public health facilities under the National Immunization Schedule. Despite the free hepatitis vaccination program in India, coverage and awareness are low. Low awareness, followed by low coverage of hepatitis vaccination, can prove dangerous for the Indian population in the long run. A majority of chronic hepatitis cases progress silently to end-stage liver disease without having many signs and symptoms. Once occurred, a complete cure is not possible with currently available drugs. The studies from neighboring countries such as China and Taiwan documented that the impact of single-dose booster for children of 10 years has made a significant difference from the cost-effectiveness perspective. They have also included the booster dose in their national vaccination program. Considering the low level of vaccination awareness, small coverage, high disease burden, and high treatment cost, now, it is high time for India to introduce hepatitis B booster vaccine. en_US
dc.identifier.doi 10.4103/ijcm.IJCM_439_19
dc.identifier.issn 0970-0218
dc.identifier.issn 1998-3581
dc.identifier.scopus 2-s2.0-85102501826
dc.identifier.uri https://doi.org/10.4103/ijcm.IJCM_439_19
dc.identifier.uri https://hdl.handle.net/20.500.14365/2625
dc.language.iso en en_US
dc.publisher Wolters Kluwer Medknow Publications en_US
dc.relation.ispartof Indıan Journal of Communıty Medıcıne en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Booster dose en_US
dc.subject hepatitis B en_US
dc.subject vaccine en_US
dc.subject Natural-History en_US
dc.subject Virus Infection en_US
dc.subject Risk-Factors en_US
dc.subject Follow-Up en_US
dc.subject Disease en_US
dc.subject Epidemiology en_US
dc.subject Prevalence en_US
dc.subject Antigen en_US
dc.title Is It the Right Time To Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? an Analysis From the Available Evidence en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Gokdemir, Ozden/0000-0002-0542-5767
gdc.author.id Abu Bashar/0000-0002-0868-8335
gdc.author.id Thiyagarajan, Arulmani/0000-0002-0413-1599
gdc.author.scopusid 57226886109
gdc.author.scopusid 57191727621
gdc.author.scopusid 57193518569
gdc.author.scopusid 57208205338
gdc.author.scopusid 57212846483
gdc.author.wosid Gokdemir, Ozden/W-1663-2017
gdc.author.wosid Abu Bashar/ABC-9917-2020
gdc.author.wosid Thiyagarajan, Arulmani/R-4830-2018
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C4
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp [Bhattacharya, Sudip] Himalayan Inst Med Sci, Dept Community Med, Dehra Dun, Uttarakhand, India; [Gokdemir, Ozden] Izmir Univ Econ, Fac Med, Izmir, Turkey; [Bashar, Md Abu] MM Deemed Univ, MM Inst Med Sci & Res, Dept Community Med, Mullana, Haryana, India; [Thiyagarajan, Arulmani] SRM Univ, Sch Publ Hlth, Chennai, Tamil Nadu, India; [Singh, Amarjeet] PGIMER, Dept Community Med, Chandigarh, India; [Singh, Amarjeet] PGIMER, Sch Publ Hlth, Chandigarh, India en_US
gdc.description.endpage 6 en_US
gdc.description.issue 1 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 4 en_US
gdc.description.volume 46 en_US
gdc.description.wosquality Q4
gdc.identifier.openalex W3133953255
gdc.identifier.pmid 34035566
gdc.identifier.wos WOS:000625839200002
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 3.0
gdc.oaire.influence 2.73671E-9
gdc.oaire.isgreen true
gdc.oaire.keywords vaccine
gdc.oaire.keywords View Point
gdc.oaire.keywords hepatitis b
gdc.oaire.keywords Public aspects of medicine
gdc.oaire.keywords RA1-1270
gdc.oaire.keywords booster dose
gdc.oaire.popularity 3.927672E-9
gdc.oaire.publicfunded false
gdc.oaire.sciencefields 03 medical and health sciences
gdc.oaire.sciencefields 0302 clinical medicine
gdc.openalex.collaboration International
gdc.openalex.fwci 0.5974
gdc.openalex.normalizedpercentile 0.67
gdc.opencitations.count 4
gdc.plumx.crossrefcites 3
gdc.plumx.mendeley 18
gdc.plumx.pubmedcites 2
gdc.plumx.scopuscites 2
gdc.scopus.citedcount 2
gdc.virtual.author Gökdemir, Özden
gdc.wos.citedcount 3
relation.isAuthorOfPublication 08a3e332-10ab-4fe4-8e7e-93001bc5aa98
relation.isAuthorOfPublication.latestForDiscovery 08a3e332-10ab-4fe4-8e7e-93001bc5aa98
relation.isOrgUnitOfPublication 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd
relation.isOrgUnitOfPublication fbc53f3e-d1d3-4168-afd8-e42cd20bddd9
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2625.pdf
Size:
353.06 KB
Format:
Adobe Portable Document Format